Growth hormone treatment for sustained pain reduction and improvement in quality of life in severe fibromyalgia

Pain

Volumn 153, Issue 7, 2012, Pages 1382-1389

  Cuatrecasas, Guillem ^a   Alegre, C ^b   Fernandez Sola J ^c   Gonzalez, M J ^b   Garcia Fructuoso, F ^d   Poca Dias, V ^d   Nadal, A ^a   Cuatrecasas, Gabriel ^a   Navarro, F ^e   Mera, A ^f   Lage, M ^f   Peino R ^f   Casanueva, F ^f   Linan C ^d   Sesmilo, G ^b   Coves, M J ^g   Izquierdo, J P ^h   Alvarez, I ^h   Granados, E ^h   Puig Domingo, M ⁱ  

^a CENTRO MÉDICO TEKNON   (Spain)

^b INSTITUT UNIVERSITARI DEXEUS   (Spain)

^c UNIVERSITY OF BARCELONA   (Spain)

^d Centro Internacional de Medicina Avanzada   (Spain)

^e HOSPITAL GENERAL UNIVERSITARIO DE ELCHE   (Spain)

^f HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^g HOSPITAL CLÍNIC   (Spain)

^h Merck SL   (Spain)

ⁱ HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Adult growth hormone deficiency; EQ5D; Fatigue; Fibromyalgia; FIQ; GH; Growth hormone; IGF 1; Pain; Safety; VAS

Indexed keywords

GROWTH HORMONE; PLACEBO; SOMATOMEDIN C;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FEMALE; FIBROMYALGIA; FOLLOW UP; HEALTH SURVEY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SINGLE BLIND PROCEDURE; SLEEP APNEA SYNDROME; TREATMENT OUTCOME; VISUAL ANALOG SCALE;

ADULT; FEMALE; FIBROMYALGIA; FOLLOW-UP STUDIES; GROWTH HORMONE; HUMANS; MIDDLE AGED; PAIN; PAIN MEASUREMENT; QUALITY OF LIFE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862500767     PISSN: 03043959     EISSN: 18726623     Source Type: Journal    
DOI: 10.1016/j.pain.2012.02.012     Document Type: Article

References (29)

1. Amundson E, Boman UW, Barrenäs ML, Bryman I, Landin-Wilhelmsen K. Impact of growth hormone therapy on quality of life in adults with Turner syndrome. J Clin Endocrinol Metab 2010;95:1355-9.
2. Annemans L, Wessely S, Spaepen E, Caekelbergh K, Caubère JP, Le Lay K, Taïeb C. Health economic consequences related to the diagnosis of fibromyalgia syndrome. Arthritis Rheum 2008;58:895-902. (Pubitemid 351364892)
3. Arnold L, Mease P, Silverman S. Pregabalin: an alpha2-delta (alpha2-delta) ligand for the management of fibromyalgia. Am J Manage Care 2010;16:S138-43.
4. Bazzichi L, Rossi A, Giuliano T, De Feo F, Giacomelli C, Consensi A, Ciapparelli A, Consoli G, Dell'osso L, Bombardieri S. Association between thyroid autoimmunity and fibromyalgic disease severity. Clin Rheumatol 2007;26:2115-20. (Pubitemid 350120351)
5. Bennett RM. Rational management of fibromyalgia. Rheum Dis Clin North Am 2002;28:xiii-xv.
6. Bennett RM, Clark SC, Walczyk J. A randomized, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998;104:227-31. (Pubitemid 28163166)
7. Bennett RM, Cook DM, Clark SR, Burckhardt CS, Campbell SM. Hypothalamic-pituitary-insulin-like growth factor-I axis dysfunction in patients with fibromyalgia. J Rheumatol 1997;24:1384-9. (Pubitemid 27353385)
8. Carville SF, Arendt-Nielsen S, Bliddal H, Blotman F, Branco JC, Buskila D, Da Silva JA, Danneskiold-Samsøe B, Dincer F, Henriksson C, Henriksson KG, Kosek E, Longley K, McCarthy GM, Perrot S, Puszczewicz M, Sarzi-Puttini P, Silman A, Späth M, Choy EH, EULAR. EULAR evidence-based recommendations for the management of fibromyalgia syndrome. Ann Rheum Dis 2008;67:536-41. (Pubitemid 351498437)
9. Collado A, Alijotas J, Benito P, Alegre C, Romera M, Sañudo I, Martín R, Peri JM, Cots JM. Consensus report on the diagnosis and treatment of fibromyalgia in Catalonia. Med Clin (Barc) 2002;118:745-9. (Pubitemid 34662029)
10. Cuatrecasas G. Fibromyalgic syndromes: could growth hormone therapy be beneficial? Pediatr Endocrinol Rev 2009;6:529-33.
11. Cuatrecasas G, Gonzalez MJ, Alegre C, Sesmilo G, Fernandez-Solà J, Casanueva FF, Garcia-Fructuoso F, Poca-Dias V, Izquierdo JP, Puig-Domingo M. High prevalence of growth hormone deficiency in severe fibromyalgia syndromes. J Clin Endocrinol Metab 2010;95:4331-7.
12. Cuatrecasas G, Riudavets C, Güell MA, Nadal A. Growth hormone as concomitant treatment in severe fibromyalgia associated with low IGF-1 serum levels. A pilot study. BMC Musculoskelet Disord 2007;30:119.
13. Cuneo RC, Judd S, Wallace JD, Perry-Keene D, Burger H, Lim-Tio S, Strauss B, Stockigt J, Topliss D, Alford F, Hew L, Bode H, Conway A, Handelsman D, Dunn S, Boyages S, Cheung NW, Hurley D. The Australian Multicenter Trial of Growth Hormone (GH) treatment in GH-deficient adults. J Clin Endocrinol Metab 1998;83:107-16. (Pubitemid 28498319)
14. Giesecke T, Williams DA, Harris R, Cupps TR, Tian X, Tian TX, Gracely RH, Clauw DJ. Subgrouping of fibromyalgia patients on the basis of pressure-pain thresholds and psychological factors. Arthritis Rheum 2003;48:2916-22. (Pubitemid 37280621)
15. Hudson SB, Schroeder DR, Bailey JN, Mielke KL, Erickson D, Miles JM, Bowers CY, Veldhuis JD. Pre- vs postmenopausal age, estradiol, and peptidesecretagogue type determine pulsatile growth hormone secretion in healthy women: studies using submaximal agonist drive and an estrogen clamp. J Clin Endocrinol Metab 2010;95:353-60.
16. Lamotte M, Maugars Y, Le Lay K, Taïeb C. Health economic evaluation of outpatient management of fibromyalgia patients and the costs avoided by diagnosing fibromyalgia in France. Clin Exp Rheumatol 2010;28:S64-70.
17. Lathe R. Hormones and the hippocampus. J Endocrinol 2001;169:205-31. (Pubitemid 32447603)
18. Leal-Cerro A, Povedano J, Astorga R, Gonzalez M, Silva H, Garcia-Pesquera F, Casanueva FF, Dieguez C. The growth hormone (GH)-releasing hormone-GHinsulin- like growth factor-1 axis in patients with fibromyalgia syndrome. J Clin Endocrinol Metab 1999;84:3378-81. (Pubitemid 30646970)
19. Moldofsky H, Inhaber NH, Guinta DR, Alvarez-Horine SB. Effects of sodium oxybate on sleep physiology and sleep/wake-related symptoms in patients with fibromyalgia syndrome: a double-blind, randomized, placebo-controlled study. J Rheumatol 2010;37:2156-66.
20. Owen RT. Milnacipran hydrochloride: its efficacy, safety and tolerability profile in fibromyalgia syndrome. Drugs Today 2008;44:653-60.
21. Paiva ES, Deodhar A, Jones KD, Bennett R. Impaired growth hormone secretion in fibromyalgia patients: evidence for augmented hypothalamic somatostatin tone. Arthritis Rheum 2002;46:1344-50. (Pubitemid 34525844)
22. Picavet HS, Hoeymans N. Health related quality of life in multiple musculoskeletal diseases: SF-36 and EQ-5D in theDMC3 study. Ann Rheum Dis 2004;63:723-9. (Pubitemid 38658404)
23. Mäkelä M, Heliövaara M. Prevalence of primary fibromyalgia in the Finnish population. BMJ 1991;303:216-9.
24. Rivera J, Gonzalez T. The Fibromyalgia Impact Questionnaire: a validated Spanish version to assess the health status in women with fibromyalgia. Clin Exp Rheumatol 2004;22:554-60.
25. Suarez-Almazor M, Looney C, Liu Y, Cox V, Pietz K, Marcus DM. A randomized controlled trial of acupuncture for osteoarthritis of the knee: effects of patientprovider communication. Arthritis Care Res 2010;62:1229-36.
26. Tanriverdi F, Karaca Z, Unluhizarci K, Kelestimur F. The hypothalamopituitary- adrenal axis in chronic fatigue syndrome and fibromyalgia syndrome. Stress 2007;10:13-25. (Pubitemid 46440564)
27. Ursini F, Pipicelli G, Grembiale RD. Efficacy and safety of duloxetine in fibromyalgia. Clin Ther 2010;161:391-5.
28. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the Multicenter Criteria Committee. Arthritis Rheum 1990;33:160-72. (Pubitemid 20098653)
29. Wolfe F. New American College of Rheumatology criteria for fibromyalgia: a twenty-year journey. Arthritis Care Res 2010;62:583-4.